ArticleAnnals of medicine and surgery (2012)2026
An uncommon multimodal management approach for low-grade appendiceal mucinous neoplasm with pseudomyxoma peritonei and mucinous borderline ovarian tumor.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: Low-grade appendiceal mucinous neoplasm (LAMN) is a rare epithelial tumor characterized by mucin production and potential dissemination into the peritoneal cavity, resulting in pseudomyxoma peritonei (PMP). The coexistence of LAMN with a mucinous borderline ovarian tumor (MBOT) represents a complex and exceedingly rare clinical scenario. Unlike the main introduction, this abstract focuses on the clinical and therapeutic significance rather than epidemiology. There are no standardized treatment protocols for synchronous LAMN with MBOT; hence, individualized management is essential. This report highlights an uncommon multimodal strategy combining cytoreductive surgery (CRS), modified FOLFIRINOX chemotherapy incorporating irinotecan, and planned second-look surgery with hyperthermic intraperitoneal chemotherapy (HIPEC). Case presentation: A 44-year-old woman presented with abdominal distension. Imaging revealed diffuse mucinous peritoneal deposits, thickened appendix, and multilocular ovarian cyst. Preoperative CA-125 was 142 U/mL, and CA 19-9 was 280 U/mL. CRS including appendectomy, right hemicolectomy, omentectomy, and bilateral salpingo-oophorectomy was performed. Histopathology confirmed LAMN with PMP and MBOT. The Peritoneal Cancer Index at primary surgery was 18. A multidisciplinary team recommended systemic chemotherapy with modified FOLFIRINOX including irinotecan before second-look HIPEC. The patient tolerated the regimen well. Clinical discussion: This case underscores an emerging role of irinotecan-based chemotherapy as part of a tailored multimodal treatment for low-grade mucinous neoplasms, especially in resource-constrained environments. Conclusion: The patient remained disease-free at 1-year follow-up, highlighting the potential effectiveness and practicality of irinotecan-based regimens as part of an individualized management strategy for low-grade mucinous neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.